The IRA & Uncertain Times for US Pharma
As part of our Transformative 2023: Regional Pharma Trends report, PharmaBoardroom’s Louis Haynes takes a look at a watershed year for drug pricing in the planet’s most lucrative pharma market.…
Louis was the Senior Analyst and Editor-in-Chief from 2013 to 2019. He currently collaborates with PharmaBoardroom as external editor. Having directed pharmaceuticals & life science projects across 4 continents, he has published over 30 country reports as well as produced analytical studies on trends in blockchain, Pharma M&A and biotechnology. He has a professional background in consultan more...
As part of our Transformative 2023: Regional Pharma Trends report, PharmaBoardroom’s Louis Haynes takes a look at a watershed year for drug pricing in the planet’s most lucrative pharma market.…
Last year’s COP28 summit saw a host of pharma players touting their green credentials, as PharmaBoardroom’s Louis Haynes explores here. This is an extract from our Transformative 2023: Regional Pharma…
Morocco is currently implementing the most ambitious, far-reaching, and comprehensive health system reorganizations in its history. “What sets this reform apart from all that has happened before is just how…
Long considered a destination of choice for life science multinationals seeking to tap into the latent potential of Middle Eastern markets, the United Arab Emirates’ pharmaceuticals, medtech and healthcare sectors…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda.…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market when the promise seems…
Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about its potential as…
In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are…
This piece forms part of InFocus Biotechs to Watch Switzerland 2021, a deep dive into the Swiss biotech ecosystem and fundamentals, featuring data sets, feature articles, and profiles of some…
One of the main supporting pillars of Singapore’s pharmaceutical industry is its magnificent manufacturing base. Not only does the city-state rank as one of the few countries on the planet…
See our Cookie Privacy Policy Here
